Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125620312 | 12562031 | 2 | F | 20120329 | 20160902 | 20160715 | 20160908 | EXP | JP-009507513-1208JPN009255 | MERCK | CHIKUBA N. II-P-394. THREE CASES OF TYPE 2 DIABETES MELLITUS WITH PANCREATITIS-RELATED ENZYME FLARES AFTER DISCONTINUATION OF ORAL DPPIV INHIBITOR DUE TO INCREASE OF THE ENZYMES DURING THE TREATMENT. THE 59TH ANNUAL MEETING OF THE JAPAN DIABETES SOCIETY. 2016 | 45.00 | YR | M | Y | 69.00000 | KG | 20160908 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125620312 | 12562031 | 1 | PS | JANUVIA | SITAGLIPTIN PHOSPHATE | 1 | Oral | 50 MG, QD | Y | 21995 | 50 | MG | TABLET | QD | |||||
| 125620312 | 12562031 | 2 | C | AMARYL | GLIMEPIRIDE | 1 | Oral | 1.5 MG, QD | U | 0 | 1.5 | MG | TABLET | QD | |||||
| 125620312 | 12562031 | 3 | C | ACTOS | PIOGLITAZONE HYDROCHLORIDE | 1 | Oral | 15 MG, QD | U | 0 | 15 | MG | TABLET | QD | |||||
| 125620312 | 12562031 | 4 | C | ACTOS | PIOGLITAZONE HYDROCHLORIDE | 1 | Oral | 30 MG, QD | U | 0 | 30 | MG | TABLET | QD | |||||
| 125620312 | 12562031 | 5 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | Oral | 5 MG, QD | U | 0 | 5 | MG | TABLET | QD | |||||
| 125620312 | 12562031 | 6 | C | MEDET | METFORMIN HYDROCHLORIDE | 1 | Oral | 250 MG, TID | U | 0 | 250 | MG | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125620312 | 12562031 | 1 | Type 2 diabetes mellitus |
| 125620312 | 12562031 | 2 | Type 2 diabetes mellitus |
| 125620312 | 12562031 | 3 | Type 2 diabetes mellitus |
| 125620312 | 12562031 | 5 | Hyperlipidaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125620312 | 12562031 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125620312 | 12562031 | Pancreatic enzyme abnormality | |
| 125620312 | 12562031 | Pancreatitis acute | |
| 125620312 | 12562031 | Pancreatitis chronic |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125620312 | 12562031 | 1 | 20100428 | 20120329 | 0 | |
| 125620312 | 12562031 | 2 | 20110803 | 0 | ||
| 125620312 | 12562031 | 3 | 20110713 | 0 | ||
| 125620312 | 12562031 | 4 | 201207 | 0 | ||
| 125620312 | 12562031 | 5 | 20100428 | 0 | ||
| 125620312 | 12562031 | 6 | 201004 | 201312 | 0 |